"We delivered an excellent second quarter with stronger than expected revenue growth, significant margin expansion, and double digit EPS growth." (CEO)
"Our strategic pricing capability delivered approximately 200 basis points of pricing in Q2, putting us on a path to exceed our initial full year goal of 100 basis points." (CEO)
"The tariff task force achieving full mitigation of the incremental tariffs that began in late spring." (CEO)
"We are also increasing our expectations on the bottom line. With updated EPS guidance of $6.00 to $6.10 for the full year, an increase of $0.08 at the midpoint." (CEO)
"Our guide does not include the impact of Biocare nor any benefit from potential tariff refunds." (CFO)
Prepared Metrics
Metric
Value
Speaker/Context
Revenue
$1.83B
Q2 reported (CEO)
Core revenue growth
6.3%
Q2 YoY (CEO)
Operating margin
26.4%
Q2 non-GAAP (CEO)
EPS
$1.49
Q2 non-GAAP (CEO)
Gross margin
55.0%
Q2 (CFO)
Operating cash flow
$277M
Q2 (CFO)
CapEx
$76M
Q2 (CFO)
Share repurchases
$65M
Q2 (CFO)
Dividends paid
$72M
Q2 (CFO)
Net leverage ratio
0.7x
End of Q2 (CFO)
FY26 revenue guidance
$7.39B–$7.49B
Reported (CFO)
FY26 core growth guidance
4.5%–6.0%
Full year (CFO)
FY26 EPS guidance
$6.00–$6.10
Non-GAAP (CFO)
Q3 revenue guidance
$1.83B–$1.85B
Reported (CFO)
Q3 EPS guidance
$1.48–$1.50
Non-GAAP (CFO)
Q&A Batch (1-5 of 10)
Q1 — Vijay Kumar
Topic: CAM growth drivers, A&G trends, and margin progression
China stimulus orders expected late year, revenue in early next year.
Mgmt stance: Bullish — confident in H2 execution, innovation, and structural improvements; cautious on comps but sees multiple upside levers.
Q&A Batch (6-10 of 10)
Q6 — Michael Ryskin
Topic: China market performance and A&G outlook
Key points:
China market stable at ~$300M/quarter; Q2 saw larger-than-expected softness due to Lunar New Year, but H1 was flattish; management remains confident in flattish guide.
Company is under-indexed to DX and pharma, over-indexed to applied in China; biotech growing high teens, a bright spot.
China A&G very soft in Q2 due to tightened/delayed government spend; Americas A&G roughly flat; Europe recovering in Germany, UK, Spain; US A&G is ~3–4% of sales with uncertainty around multi-year grants.
Mgmt stance: Neutral – China stable but muted; long-term optimism driven by installed base, innovation, alignment with China 5-year plan (AI, healthcare, green, PFAS regulations), and expected stimulus early next year.
Q7 — Dan Leonard
Topic: Spectroscopy replacement cycle and growth outlook
Key points:
Spectroscopy seeing momentum from semiconductors and data center capacity build-up; pent-up demand from muted replacement cycle in prior years.
New product launch expected to drive acceleration; company is absolute market leader with trusted customer relationships.
Management describes this as “just the beginning” with multiple fronts of momentum.
Mgmt stance: Bullish – strong momentum from diverse applications, new innovation, and leadership position; expects continued acceleration.
Q8 — Analyst (unnamed)
Topic: Margin commentary and investment pull-forward
Key points:
Strong Q2 margin from volume leverage; investments in innovation (e.g., ICP-MS launch) were planned, not pulled forward in timing.
Full-year margin guide raised 10 bps at midpoint (to +85 bps increase at midpoint); incorporates structural improvements from Ignite, volume leverage, offset by inflation (broad, Middle East logistics, AI/chip costs) and growth investments.
Mgmt stance: Neutral – investments were always planned; margin guide raised modestly, reflecting balanced view of leverage and headwinds.
Q9 — Catherine Schulte
Topic: Food business decline and outlook
Key points:
Food market declined -3% in Q2 vs. mid-single-digit guide; primary driver was delayed government spending in Asia.
Americas and Europe grew high single digits in Q2; FY 2026 guidance reduced to flat to low-single-digit negative.
China stimulus from last year creates tough comp for FY 2026; Middle East conflict adds pressure on food shipments/testing in Asia.
Long-term drivers: ever-changing food safety regulations, demand for healthier/sustainable foods, contract lab sample volumes, PFAS in food.
Mgmt stance: Neutral – challenging quarter, but long-term outlook strong due to structural growth drivers.
Q10 — Casey Woodring
Topic: Forensic TSA one-timer and chemical CapEx in CAM
Key points:
Forensic TSA win of $9M last quarter; $5M recognized in Q2; first contract deployed ahead of FIFA World Cup 2026; positions for future addendums and larger aviation security tenders.
Chemical CapEx in CAM is strong across all regions, not limited to US; funnels geographically diverse.
Mgmt stance: Bullish – TSA solution highly differentiated with strong positioning; chemical CapEx broad-based and robust.